ATE280586T1 - Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon - Google Patents

Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon

Info

Publication number
ATE280586T1
ATE280586T1 AT00918952T AT00918952T ATE280586T1 AT E280586 T1 ATE280586 T1 AT E280586T1 AT 00918952 T AT00918952 T AT 00918952T AT 00918952 T AT00918952 T AT 00918952T AT E280586 T1 ATE280586 T1 AT E280586T1
Authority
AT
Austria
Prior art keywords
hiv
protein
vaccine containing
tat
vaccine
Prior art date
Application number
AT00918952T
Other languages
English (en)
Inventor
Erwann Loret
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904610A external-priority patent/FR2792204B1/fr
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE280586T1 publication Critical patent/ATE280586T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00918952T 1999-04-13 2000-04-12 Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon ATE280586T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR9916633A FR2792206B1 (fr) 1999-04-13 1999-12-29 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
PCT/FR2000/000938 WO2000061067A2 (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1

Publications (1)

Publication Number Publication Date
ATE280586T1 true ATE280586T1 (de) 2004-11-15

Family

ID=26234914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918952T ATE280586T1 (de) 1999-04-13 2000-04-12 Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon

Country Status (20)

Country Link
US (1) US7087377B2 (de)
EP (1) EP1169057B1 (de)
JP (1) JP4860823B2 (de)
KR (1) KR100725637B1 (de)
AT (1) ATE280586T1 (de)
AU (1) AU775560B2 (de)
BR (1) BR0009758A (de)
CA (1) CA2370563C (de)
DE (1) DE60015312T2 (de)
DK (1) DK1169057T3 (de)
ES (1) ES2231178T3 (de)
FR (1) FR2792206B1 (de)
HK (1) HK1044463B (de)
HU (1) HUP0200841A2 (de)
IL (2) IL145884A0 (de)
MX (1) MXPA01010482A (de)
NO (1) NO326603B1 (de)
PL (1) PL197666B1 (de)
PT (1) PT1169057E (de)
WO (1) WO2000061067A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100465589B1 (ko) * 2001-04-20 2005-01-13 허만욱 비만 억제 폴리펩타이드
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
ES2500265T3 (es) * 2008-04-22 2014-09-30 Université D'aix-Marseille Proteína Tat Oyi mutada para prevenir o tratar SIDA
EP2411043B1 (de) * 2009-03-23 2013-07-31 PIN Pharma, Inc. Krebsbehandlung mit immunstimulierenden hiv-tat-derivat-polypeptiden
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
WO2011128720A1 (en) * 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
RU2653754C2 (ru) 2012-12-06 2018-05-14 Пин Фарма, Инк. Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
CN105705164A (zh) 2013-10-04 2016-06-22 品诺制药公司 用于癌症治疗的免疫刺激性hiv tat衍生多肽
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5019510A (en) 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
ATE196255T1 (de) * 1995-03-08 2000-09-15 Neovacs Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.
DE19514089C2 (de) * 1995-04-13 1997-07-10 Deutsches Krebsforsch Nachweisverfahren für HIV-TAT
JPH10212300A (ja) * 1996-11-26 1998-08-11 Sankyo Co Ltd ペプチドワクチン
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
US20050106161A1 (en) 2005-05-19
WO2000061067A3 (fr) 2001-03-29
WO2000061067A2 (fr) 2000-10-19
PL197666B1 (pl) 2008-04-30
NO20014841D0 (no) 2001-10-04
AU775560B2 (en) 2004-08-05
HK1044463A1 (en) 2002-10-25
WO2000061067B1 (fr) 2001-05-10
JP2002541165A (ja) 2002-12-03
PL353033A1 (en) 2003-10-06
EP1169057A2 (de) 2002-01-09
DK1169057T3 (da) 2005-03-07
AU3972400A (en) 2000-11-14
KR100725637B1 (en) 2007-06-07
CA2370563A1 (fr) 2000-10-19
US7087377B2 (en) 2006-08-08
DE60015312D1 (de) 2004-12-02
IL145884A (en) 2007-09-20
NO326603B1 (no) 2009-01-19
MXPA01010482A (es) 2002-09-18
EP1169057B1 (de) 2004-10-27
FR2792206A1 (fr) 2000-10-20
IL145884A0 (en) 2002-07-25
BR0009758A (pt) 2002-01-08
JP4860823B2 (ja) 2012-01-25
ES2231178T3 (es) 2005-05-16
FR2792206B1 (fr) 2006-08-04
NO20014841L (no) 2001-11-27
CA2370563C (fr) 2013-12-17
HUP0200841A2 (en) 2002-07-29
PT1169057E (pt) 2005-03-31
HK1044463B (zh) 2005-06-03
DE60015312T2 (de) 2006-02-09
KR20020005675A (ko) 2002-01-17

Similar Documents

Publication Publication Date Title
ATE280586T1 (de) Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
FI893962A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat hyödyllisiä AIDS:in hoidossa
FI906212A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDSin hoidossa
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
FI891716A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat käyttökelpoisia AIDS'in hoidossa
BR0108210A (pt) Vacina contra o vìrus da imunodeficiência humana
NL300808I2 (nl) susoctocog alfa
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
DE69833160D1 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
ATE383424T1 (de) Polypeptide, deren herstellung und verwendung
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
EP0676954A4 (de) Hiv-lockvirus.
DK300287D0 (da) Kondenserede cycliske azepin-2-oner, og deres anvendelse som antihypertensive laegemidler
FI923158A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoidossa
GR880100152A (el) Συνθεσεις για την περιποιηση της επιδερμιδος.
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
SE9101815L (sv) Behandling av sjukdom foerbunden med hiv-infektioner
DE3750636D1 (de) Herstellung von Titan-, Magnesium- und Zirkon-Calcium-Oxiden.
DE60108976D1 (de) Vorrichtung zur unterstützung von aktivitäten
ATE103980T1 (de) Das f-protein vom aids-virus enthaltender impfstoff.
BR0108723A (pt) Medicamentos contra doenças viróticas
FI881123A7 (fi) Human Immunodeficiency Viruksen (HIV) inaktivoiminen proteiinipitoisissa liuoksissa fenolilla.
DE60210936D1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169057

Country of ref document: EP